In the largest-ever randomized trial of antihypertensive drug treatment in sub-Saharan Africa, two medication combinations including the long-acting calcium channel blocker amlodipine outperformed a third two-drug combination featuring a diuretic and an angiotensin-converting-enzyme (ACE) inhibitor.

Hypertensive patients from the RADIANCE-HTN SOLO trial who received renal denervation sustained a lower blood pressure through six months compared to participants randomized to a sham procedure, despite being placed on fewer antihypertensive medications during follow-up.

Researchers from the Rochester Institute of Technology are leveraging “natural processes” to provide insights into heart health with a toilet seat-based cardiovascular monitoring system.

A post-FDA approval study of Abbott’s CardioMEMS heart failure sensor found the device reduced HF-related hospitalizations by 58 percent in a trial group of 1,200 patients, researchers reported at this year’s American College of Cardiology symposium in New Orleans.

A catheter ablation protocol for atrial fibrillation (AFib) including only “the bare essentials” of the procedure delivered similar outcomes as a more involved strategy featuring pulmonary vein mapping, according to research presented at EHRA 2019.

NEW ORLEANS — A new analysis considering not only a patient's first cardiovascular event—but the second, third and beyond—paints the REDUCE-IT trial in an even more positive light. 

NEW ORLEANS — An antithrombotic regimen of apixaban plus a P2Y12 inhibitor such as clopidogrel lowered bleeding events and hospitalizations compared to warfarin plus clopidogrel in a cohort of patients with atrial fibrillation (AFib) and a recent acute coronary syndrome (ACS), according to results of the AUGUSTUS trial.

NEW ORLEANS — Patients who received the MitraClip device to treat heart failure with secondary mitral regurgitation showed significant and lasting improvements on a quality-of-life assessment compared to people treated with optimal medical therapy alone, according to a substudy of the COAPT trial presented at the American College of Cardiology’s scientific sessions.